The effect of lipid lowering medication on lipid accumulation in patients with neutral lipid storage disease with muscle weakness.
- Conditions
- eutral lipid storage disease with myopathyMedDRA version: 13.1Level: PTClassification code 10007636Term: CardiomyopathySystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 13.1Level: HLGTClassification code 10013317Term: Lipid metabolism disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 13.1Level: PTClassification code 10028641Term: MyopathySystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Registration Number
- EUCTR2011-001205-27-NL
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients need to have NLSDM; as there are only 6 patients in the world and 2 of them in the Netherlands, we aim to include both patients.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
This is more a case study, therefore we don't have any exclusion criteria.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method